Amplia Therapeutics CEO says dosing in its phase one trial is 'enormous' milestone

Amplia Therapeutics Limited's (ASX:ATX) Dr John Lambert speaks to Proactive's Andrew Scott following the news they've begun dosing the first volunteers in its Phase 1 clinical trial of AMP945. The molecule's being developed for difficult-to-treat cancers and fibrotic diseases. Amplia expects to complete dosing in the trial during the first half of next year, which should allow reporting of top-line results around the middle of 2021. 

To view media story please click here.